What Researchers Did
This systematic review discussed the current understanding of bronchopulmonary dysplasia-associated pulmonary hypertension (BPD-PH) in preterm infants and highlighted potential new ways to predict and treat the condition.
What They Found
The researchers found that bronchopulmonary dysplasia-associated pulmonary hypertension (BPD-PH) affects 17-24% of infants with bronchopulmonary dysplasia (BPD). BPD-PH significantly increases the risk of illness and death, with mortality rates reaching up to 50% in affected infants. Currently, there is no safe and effective treatment for BPD and BPD-PH.
What This Means for Canadian Patients
This study highlights the severe health challenges faced by preterm infants with BPD-PH, a condition that significantly increases their risk of illness and death. For Canadian families, this means that preterm infants with BPD-PH face a serious condition with limited treatment options, underscoring the need for better diagnostic tools and therapies. The review's focus on emerging biomarkers could eventually lead to earlier identification and improved care strategies for these vulnerable infants in Canada.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
As a review, this study synthesizes existing research and does not present new experimental data or clinical trial results.